URGN — UROGEN PHARMA LTD
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying URGN?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their URGN position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +4 tracked investors reported holding URGN at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About UROGEN PHARMA LTD (URGN)
UROGEN PHARMA LTD (URGN) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $56M. Across recent filings, tracked investors recorded 1 new positions, 3 increased, 7 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in URGN
How many top investors track URGN
A small number of top investors own this.
URGN Ownership Composition
How UROGEN PHARMA LTD is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant94.4%
- Growth & Innovation5.6%
Tracked investors currently reporting URGN
1 tracked investor has since exited this position — listed separately below.
- Steve CohenJun 30, 2026Point72 Asset ManagementShares1.5MValue$56.1M% Portfolio0.06%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares106.7KValue$3.9M% Portfolio0.00%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares80.3KValue$3M% Portfolio0.00%
- Cathie WoodJun 30, 2026ARK Investment ManagementShares101.5KValue$3.7M% Portfolio0.02%
Previously held URGN
These investors reported URGN in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Paul Tudor Jones | Tudor Investment Corp | 16.5K | $226.1K | Jun 30, 2025 |
Recent activity
- Reduced$2.4M(-24.97%)Jan 17, 2024
- Reduced$2.2M(-9.41%)Apr 18, 2024
- Increased$2.5M(3.73%)Jul 26, 2024
- Reduced$1.5M(-19.86%)Oct 31, 2024
- Increased$1.5M(15.22%)Feb 4, 2025
- Increased$2.1M(32.57%)May 7, 2025
- Reduced$2.3M(-10.60%)Jul 30, 2025
- Reduced$2.8M(-4.13%)Feb 11, 2026
- Reduced$2.1M(-4.89%)May 12, 2026
- Reduced$3.7M(-12.15%)Aug 14, 2026
- New$3MOct 18, 2023
Frequently asked questions
- How many institutional investors hold URGN?
- 4 tracked institutional investors disclosed a position in URGN (UROGEN PHARMA LTD) in their most recent 13F filing.
- Who is the largest institutional holder of URGN?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in URGN, valued at $56M.
- Did institutional ownership of URGN increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 3 increased, 7 reduced, and 0 fully exited URGN.
- Where does this URGN ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.